Zealand Pharma A/S 2019 SR
The report highlights Zealand Pharma's commitment to developing peptide therapeutics for rare diseases, specifically gastrointestinal and metabolic conditions. In 2019, the company initiated a relocation to a more sustainable facility in Denmark and expanded its operations to the United States. Key achievements include maintaining a diverse workforce and aligning business practices with UN Sustainable Development Goals 3, 5, 10, 12, 16, and 17. The company also focused on patient-centric initiatives like LivingWithSBS.com and matured its vendor oversight program to ensure high ethical and quality standards across its outsourced business model.
Company: Zealand Pharma A/S
Sector: Manufacturing
Country: Denmark
Year: 2019
Type: SR
Pages: 16
Back to company
Zealand Pharma A/S
Corporate Responsibility Report
The report highlights Zealand Pharma's commitment to developing peptide therapeutics for rare diseases, specifically gastrointestinal and metabolic conditions. In 2019, the company initiated a relocation to a more sustainable facility in Denmark and expanded its operations to the United States. Key achievements include maintaining a diverse workforce and aligning business practices with UN Sustainable Development Goals 3, 5, 10, 12, 16, and 17. The company also focused on patient-centric initiatives like LivingWithSBS.com and matured its vendor oversight program to ensure high ethical and quality standards across its outsourced business model.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees